Intrexon | XON

Intrexon traded at $2.38 this Friday August 12th, increasing $0.06 or 2.59 percent since the previous trading session. Looking back, over the last four weeks, Intrexon gained 32.96 percent. Over the last 12 months, its price fell by 61.24 percent. Looking ahead, we forecast Intrexon to be priced at 2.01 by the end of this quarter and at 1.85 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
2.38
Daily Change
2.59%
Yearly
-61.24%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Agenus 3.01 0.34 12.55% -49.50%
Amgen 248.31 -0.04 -0.02% 8.11%
Anika Therapeutics 21.90 0.16 0.74% -46.18%
Arrowhead Research 46.78 1.15 2.52% -21.76%
AstraZeneca 10,698.00 192.00 1.83% 26.96%
Bluebird Bio 6.31 0.38 6.41% -66.49%
Bristol-Myers Squibb 74.90 0.44 0.59% 10.95%
ChemoCentryx 50.62 0.02 0.04% 253.74%
Gilead Sciences 62.68 0.23 0.37% -11.92%
GlaxoSmithKline 1,445.00 45.00 3.21% -3.14%
Heron Therapeutics 4.95 0.08 1.67% -56.26%
Immunogen 5.46 0.22 4.20% -3.19%
Incyte Corp 73.86 0.10 0.14% 0.53%
Karyopharm Therapeutics 5.25 0.29 5.85% 8.92%
Ligand Pharmaceuticals 103.31 1.34 1.31% -5.26%
MacroGenics 5.20 0.11 2.16% -78.78%
MannKind 4.17 0.10 2.46% 1.96%
Merck & Co 89.86 0.93 1.05% 17.13%
Novartis 80.09 -0.95 -1.17% -6.83%
Peregrine Pharmaceuticals 19.52 0.55 2.90% -21.16%
Rigel Pharmaceuticals 1.48 0.08 5.71% -64.16%
Roche Holding 315.40 5.25 1.69% -14.28%
Sangamo BioSciences 6.06 0.24 4.12% -39.70%
Thermo Fisher Scientific 596.53 3.99 0.67% 9.53%
Veracyte 26.06 0.57 2.24% -35.73%
Xencor 30.09 1.43 4.99% -6.67%
Intrexon 2.38 0.06 2.59% -61.24%
Ziopharm Oncology 1.79 0.01 0.28% 0.28%

Indexes Price Day Year
US2000 1993 17.76 0.90% -10.35%

Intrexon
Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. The Company is offering a class of microbe-based biopharmaceuticals that enable the expression and local delivery of disease-modifying therapeutics. Precigen is using precision technology to target intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. The Company also focused on studying life-threatening human diseases through the development of MiniSwine Yucatan miniature pig research models and services, as well as enabling the production of cells and organs in its genetically engineered swine for regenerative medicine applications. The Company’s subsidiaries include PGEN Therapeutics, Inc., Precigen ActoBio, Inc., Exemplar Genetics, LLC and Trans Ova Genetics, L.C.